Wall Street analysts are maintaining Buy rating on Esperion Therapeutics, Inc. (NASDAQ:ESPR) company shares. The one year target on the name currently stands at $55.38. The stock recently touched $15.53 and has moved in the range of $14.84 - 15.64 during the current session. Based on a recent bid this places the stock +23.16% away from the 52-week floor of $12.61 and -87.16% away from the 52-week ceiling of $120.96.
When stocks are given “Buy” ratings by analysts, the reasons or criteria for that recommendation can greatly vary. Typically when a stock is given this label, analysts are expecting that the stock will outperform their peers, their sector or the market over a 6 to 12 month time frame. Several factors might include near-term catalysts, future earnings growth. Many analysts only give a Buy recommendation when they expect that the stock will yield a return of at least 5-10% over the course of a year. Since analyst criteria and recommendation terminology can differ, we can look at consensus numbers to get a feel of overall analyst sentiment.
Sigma Designs, Inc. (NASDAQ:SIGM) has been given a consensus Buy rating by analysts on Wall Street. According to Thomson Reuters' First Call, research brokers have a one year price target of $11.00 on the stock. The stock is currently trading -4.04% away from its 200-day moving average of $7.59. Based on a recent trade, shares of Sigma Designs, Inc. are -43.26% away from the 52-week high of $12.83 and +34.57% away from the 52-week low of $5.41.
Analysts are estimating that the company will report earnings of $0.29 for the current year and $-0.01 for next quarter. The stock closed the most recent trading session at $6.88.
Shares of AEterna Zentaris Inc. (NASDAQ:AEZS) continue to be viewed favorably by equities brokerage firms on Wall Street. The First Call consensus which is calculated by Thomson Reuters has a $12.63 price target and Buy rating according to the covering analysts. During today’s session the stock hit $3.08 or N/A from the previous close, while moving in the range of $3.02 - 3.18.
Shares of BioLineRx Ltd. (NASDAQ:BLRX) continue to be viewed favorably by equities brokerage firms on Wall Street. The First Call consensus which is calculated by Thomson Reuters has a $4.83 price target according to the covering analysts. During today’s session the stock hit $1.10 or N/A from the previous close, while moving in the range of $0.96 - 1.09. This puts the stock -67.07% away from the 52-week high of $3.28 and +27.06% away from the 52-week low of $0.85.
Exact definitions of a “Buy” rating can greatly vary depending on the equity research firm. The consensus rating simply provides an average of those recommendations. It's important to note that a “Buy” rating does not mean that every investor should acquire the stock. It is just a single factor among many that should be considered before making an investment decision.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
